Key facts
- Notable investors include Zinc.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Epiome.AI
- ·The full record, as it builds
Funding rounds
No funding rounds for Epiome.AI are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epiome.AI
Developer of AI-driven epigenetic diagnostics designed to enable early detection of neurodegenerative diseases. The company is currently operating in Stealth mode.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 3
- Website
- epiome.ai/
- Ownership
- Privately Held (backing)
Epiome.AI doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epiome.AI shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epiome.AI in its N-PORT filings yet. We sweep new filings monthly.